UK fraud office acts against nine accused of generics price fixing
An investigation by the UK's Serious Fraud Office (SFO) into price fixing and market sharing by suppliers of generic drugs has led to criminal proceedings being brought.
An investigation by the UK's Serious Fraud Office (SFO) into price fixing and market sharing by suppliers of generic drugs has led to criminal proceedings being brought.
The criminal proceedings are being brought against nine individuals and five companies, alleged to have conspired to defraud in relation to the pricing and supply to the NHS of warfarin, the branded drug Marevan, and penicillin-based antibiotics between January 1996 and December 2000.
Summonses have been served upon the companies: Kent Pharmaceuticals Ltd, Norton Healthcare Ltd, Generics (UK) Ltd, Ranbaxy (UK) Ltd and Goldshield Group PLC (formerly Goldshield Pharmaceuticals Europe Ltd)
The Case Controller, assistant director Philip Lewis, said: "This important case involving an allegation of dishonest price fixing by companies is likely to have a significant impact upon the business culture of this country."